Abstract Library

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2297 Merkel Cell Carcinomas in New Zealand: Virus or Ultra Violet?

Introduction: Merkel Cell Carcinoma (MCC) is a rare Neuroendocrine skin tumour. MCC behavior is more aggressive than the more common Melanoma, with treatments often restricted to surgery or radiotherapy, although immunotherapy holds promise overseas. In 2008, a USA study identified an oncogenic polyomavirus (MCPyV) present in eight of ten tested MCC tumours. Studies from across Europe and the USA confirmed MCPyV presence in ~80% of all MCCs. However, a cohort from Australia found a rate of just 24%, suggesting an alternative mechanism; ultra violet (UV) exposure was suspected and later confirmed using genomic mutational signature analysis. Are these are two separate diseases, requiring different clinical management strategies for best patient outcomes?

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Robb T

Authors: Robb T, Woodhouse B, Parker K, Miller R, Hayward G,

Keywords: merkel, ddPCR, diagnostics, genomics,

#2256 Assessment of the Serum Levels of the Soluble Vascular Cellular Adhesion Molecule-1 (sVCAM-1) in Patients with Neuroendocrine Neoplasms

Introduction: Tumor growth and the ability to metastasize is a multistage process involving interactions between cancer cells and the vascular endothelium. These interactions have been reported to be mediated by various molecules including sVCAM-1. We have previously shown elevated serum concentration of sVCAM-1 in 82 neuroendocrine neoplasms (NEN) compared to controls. Here, we present results of the extension of the previous study.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Malczewska A

Authors: Rosiek V, Malczewska A, Kos-Kudła B,

Keywords: neuroendocrine neoplasms, adhesion molecule, metastasis,

#1898 Over Treatment Radionuclide Therapy (PRRT) of Metastatic Neuroendocrine Neoplasm (NEN) – A Case Report.

Introduction: Over treatment radionuclide therapy (PRRT) of metastatic neuroendocrine neoplasm (NEN).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Strzelczyk J, Poczkaj K, Rosiek V, Kos-Kudła B,

Keywords: neuroendocrine neoplasm, metastases, radionuclide therapy,

#1887 Neuroendocrine Neoplasm Registry: Single-Centre Experience and Outcomes

Introduction: Neuroendocrine neoplasm (NEN) registries are highly needed to investigate epidemiology of NEN, collect and deliver data on efficacy of management strategies in NEN and improve quality of NEN pts care.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Rosiek V, Strzelczyk J, Zemczak A, Kos-Kudła B,

Keywords: NEN, single-centre registry,